Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Waks AG, Winer EP. Breast Cancer Treatment: a review. JAMA. 2019;321:288–300. https://doi.org/10.1001/jama.2018.19323.

Article  CAS  PubMed  Google Scholar 

Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3–8. https://doi.org/10.1093/annonc/12.suppl_1.s3.

Article  PubMed  Google Scholar 

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37. https://doi.org/10.1038/35052073.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Volume 235. Science; 1987. pp. 177–82. (New York, N.Y.). https://doi.org/10.1126/science.3798106.

SEER. Female Breast Cancer Subtypes - Cancer Stat Facts. 19.04.2023. https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed 6 Dec 2023.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72. https://doi.org/10.1056/NEJMoa052306.

Article  CAS  PubMed  Google Scholar 

Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer. 2021;7:56. https://doi.org/10.1038/s41523-021-00265-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17:4834–43. https://doi.org/10.1158/1078-0432.CCR-10-2962.

Article  CAS  PubMed  Google Scholar 

Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast (Edinburgh Scotland). 2013;22:525–31. https://doi.org/10.1016/j.breast.2012.12.006.

Article  PubMed  Google Scholar 

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with Tucatinib Plus Trastuzumab and Capecitabine for previously treated HER2-Positive breast Cancer with Brain metastases in the HER2CLIMB trial. JCO. 2020;38:2610–9. https://doi.org/10.1200/JCO.20.00775.

Article  CAS  Google Scholar 

Corti C, Criscitiello C. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO Open. 2021;6:100063. https://doi.org/10.1016/j.esmoop.2021.100063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-Selective tyrosine kinase inhibitor Tucatinib as a single Agent or in combination with Trastuzumab or Docetaxel in Solid Tumor models. Mol Cancer Ther. 2020;19:976–87. https://doi.org/10.1158/1535-7163.MCT-19-0873.

Article  CAS  PubMed  Google Scholar 

Debbi K, Grellier N, Loganadane G, Boukhobza C, Mahé M, Cherif MA, et al. Interaction between Radiation Therapy and targeted therapies in HER2-Positive breast Cancer: literature review, levels of evidence for Safety and recommendations for Optimal Treatment sequence. Cancers (Basel). 2023. https://doi.org/10.3390/cancers15082278.

Article  PubMed  Google Scholar 

Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:1537–70. https://doi.org/10.6004/jnccn.2020.0052.

Article  PubMed  Google Scholar 

Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32:1332–47. https://doi.org/10.1016/j.annonc.2021.07.016.

Article  PubMed  Google Scholar 

Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2:1113–20.

CAS  PubMed  Google Scholar 

Yu T, Cho BJ, Choi EJ, Park JM, Kim DH, Kim IA. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. Oncotarget. 2016;7:79089–100. https://doi.org/10.18632/oncotarget.12597.

Article  PubMed  PubMed Central  Google Scholar 

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64. https://doi.org/10.1007/s10555-015-9552-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481–91. https://doi.org/10.1038/modpathol.2015.98.

Article  CAS  PubMed  Google Scholar 

Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003;9:3645–52.

CAS  PubMed  Google Scholar 

Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;86:1449–56. https://doi.org/10.1038/sj.bjc.6600286.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. The force of HER2 - A druggable target in NSCLC? Cancer Treat Rev. 2020;86:101996. https://doi.org/10.1016/j.ctrv.2020.101996.

Article  CAS  PubMed  Google Scholar 

Takegawa N, Yonesaka K. HER2 as an emerging Oncotarget for Colorectal Cancer Treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer. 2017;16:247–51. https://doi.org/10.1016/j.clcc.2017.03.001.

Article  PubMed  Google Scholar 

Greally M, Kelly CM, Cercek A. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018;42:560–71. https://doi.org/10.1016/j.currproblcancer.2018.07.001.

Article  PubMed  Google Scholar 

Wang G, He Y, Sun Y, Wang W, Qian X, Yu X, Pan Y. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clin Transl Oncol. 2020;22:813–22. https://doi.org/10.1007/s12094-019-02213-9.

Article  CAS  PubMed  Google Scholar 

Caterina Pellegrini M, Falleni A, Marchetti B, Cassani M, Miozzo F, Buttitta, et al. HER-2/Neu alterations in Non-small Cell Lung Cancer. Clin Cancer Res. 2003;9:3645–52.

PubMed  Google Scholar 

Strickler JH, Cercek A, Siena S, André T, Ng K, van Cutsem E, et al. Tucatinib plus Trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496–508. https://doi.org/10.1016/S1470-2045(23)00150-X.

Article  CAS  PubMed  Google Scholar 

Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6:100260. https://doi.org/10.1016/j.esmoop.2021.100260.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin A-M, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 2007;40:580–94.